Tegaserod pharmacokinetics

The pharmacokinetics of tegaserod in patients with IBS are comparable to those in healthy individuals, and similar between men and women. No dosage adjustment is required in elderly patients or those with mild-to-moderate hepatic or renal impairment [46,47]. 

Zhou H, Horowitz A, Ledford PC, Hubert M, Appel-Dingemanse S, Osborne S, McLeod JF. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects. J Clin Pharmacol 2001 41(10) 113. 

The effect of tegaserod on the single-dose pharmacokinetics and safety profile of theophylhne has been determined in a randomized, open, crossover study in 18 subjects (80). Tegaserod did not alter the pharmacokinetics of theophylhne and the incidence of adverse events was similar after co-administration. However, since in vitro studies have shown that tegaserod inhibits CYP1A2 (81), more evidence is needed to claim that no dosage adjustment is required when theophylhne is coadministered. 

Zhou H, Khalilieh S, Svendsen K, Pommier F, Osborne S, Appel-Dingemanse S, Lasseter K, McLeod IF. Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects. J Qin Pharmacol 2001 41(9) 987-93. 

Tegaserod does not appear to alter the pharmacokinetics of theophylline. 

---